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Abstract
Purpose The aim of this study is to characterize the patterns of
medication use by early-stage breast cancer (ESBC) survivors
from diagnosis to 1 year post-chemotherapy.
Methods A single-center longitudinal study was conducted
with ESBC patients diagnosed between December 2011 and
June 2014. Data on the medication use of individual patients
were retrieved from prescription databases, supplemented by
records from the National Electronic Health Records. The data
covered the period from ESBC diagnosis to 1 year post-che-
motherapy. Medication types were classified according to the
World Health Organization’s Anatomical Therapeutic
Chemical classification system, and medication for chronic
diseases was created by adapting a list of 20 chronic diseases
provided by the U.S. Department of Human and Health
Services.
Results Of the 107 patients involved in the study (mean
age 51.1±8.4 years; 78.5 % Chinese), 46.7 % manifested
non-cancer comorbidities, of which hypertension (24.3 %)
was the most prevalent, followed by hyperlipidemia
(13.1 %) and diabetes (5.6 %). Calcium channel blockers
(12.1 %) and lipid-modifying agents (11.2 %) were the
most common chronic medication types used before che-
motherapy, and their use persisted during chemotherapy
(10.3 and 11.2 %, respectively) and after chemotherapy
(11.2 and 13.1 %, respectively). Hormonal therapy was
the predominant post-chemotherapy medication (77.6 %).
A statistically significant increase (p<0.0001) was ob-
served in the mean number of chronic disease medication
classes prescribed to patients between the pre-
chemotherapy (0.53±1.04) and chemotherapy (0.62±1.08)
periods and between the chemotherapy and post-
chemotherapy (1.63±1.35) periods.
Conclusions There is an increase in trend of chronic medica-
tion usage in breast cancer survivors after cancer treatment.
This study provides important insights into the design of med-
ication management programs tailored to this population.
Future studies should incorporate a control population to im-
prove the interpretation of study results.
Keywords Early-stage breast cancer . Medication use .
Chemotherapy . Cancer survivor . Medicationmanagement
Introduction
According to the World Health Organization (WHO), 32.6 mil-
lion people worldwide were living with cancer in 2012.
Globally, breast cancer is the second most common form of
cancer, exhibited by approximately 19.2 % of all cancer patients
[1]. Early-stage breast cancer (ESBC) survival rates have in-
creased in the last decade. There are numerous possible expla-
nations for the increased likelihood of survival, such as the early
detection of cancer [2] and the development of more effective
systemic therapies in the form of cytotoxic chemotherapy, hor-
monal therapy, and targeted therapies [3, 4]. Due to the ageing
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population and the expected increase in breast cancer incidence,
the pool of ESBC survivors is likely to become considerably
larger in the coming decades [5, 6].
Numerous studies have shown that both the disease
and its treatment have physical and psychosocial conse-
quences for ESBC survivors [7, 8]. These may manifest
as long-term effects during active therapy or late effects
that persist for months to years after active treatment.
These effects may be temporary, progressive, or perma-
nent and range from mild to severe, debilitating, and
even life threatening. Complications may arise from sur-
gery (pain, numbness, weakness, lymphedema), chemo-
therapy (cognitive dysfunction, neuropathy, sexual dys-
function, cardiac dysfunction), radiotherapy (pain, atro-
phy, fibrosis, late cardiac effects of left breast radiation),
and the disease itself (psychosocial problems, fatigue,
pain, sleep disorder, depression/anxiety) [5, 9]. The use
of adjuvant hormonal therapy in the form of tamoxifen
has been associated with menopause-like side effects
such as hot flushes, sleep disturbance, anxiety, and an
increased risk of uterine cancer and thromboembolic
events. The use of aromatase inhibitors (AIs) is associ-
ated with vaginal dryness, arthralgia, and an increased
risk of osteoporosis and fractures. Therefore, survivors
of ESBC are likely to require different types of medi-
cation throughout their treatment journeys, primarily to
manage changes in treatment-related complications.
The majority of ESBC patients are 45–64 years old.
Therefore, most patients diagnosed with breast cancer
belong to a subset of a larger population of mid-life
women with chronic conditions such as hypertension,
dyslipidemia, diabetes mellitus, and coronary artery dis-
ease [10–12]. Otte et al. reported that the majority of
breast cancer survivors exhibit at least two non-cancer-
related comorbidities [10]. This observation is consistent
with the findings of another study, in which more than
60 % of the sampled breast cancer survivors were pre-
scribed medication for comorbidities, and 53 % reported
using non-prescription therapies concurrently [13].
Therefore, it is vital that the use of medication by breast
cancer survivors is effectively managed to facilitate
medication adherence, prevent drug–drug interaction,
and ensure the efficacy of cancer treatment and chronic
medication [10, 14].
To the best of our knowledge, few researchers have taken a
longitudinal approach to the medication use of ESBC survi-
vors. Therefore, this study was designed to characterize the
medication use of ESBC survivors by (i) identifying the prev-
alence of therapeutic classes of medication used before che-
motherapy, during chemotherapy and in the 1 year post-
chemotherapy period, and (ii) comparing the numbers of
chronic disease medication classes used by patients before,
during, and after chemotherapy.
Methodology
Study design and population
This is a single-center, retrospective study conducted at the
National Cancer Centre Singapore (NCCS). NCCS is a lead-
ing regional center for cancer research and treatment, serving
approximately 70 % of all cancer patients in Singapore. The
study participants were drawn from a patient cohort recruited
between December 2011 and June 2014 to participate in a
prospective longitudinal study designed to investigate the cog-
nitive effects of chemotherapy on ESBC patients [15]. The
current study was approved by the SingHealth Institutional
Review Board, and written informed consent was provided
by all of the study subjects.
Patients were eligible to participate in the study if they had
completed at least 1 year of follow-up treatment, dated from
the last day of their final chemotherapy cycle. The patients in
the original cohort met the following criteria for eligibility: (i)
they were aged 21 years or above, (ii) they were able to read
and understand either English or Mandarin, (iii) they had re-
ceived a diagnosis of ESBC from a medical oncologist, and
(iv) they had received either anthracycline-based or taxane-
based chemotherapy without a previous history of chemother-
apy or radiotherapy.
Data collection
A data collection form was created to obtain information on
the patients’ sociodemographic characteristics and clinical and
medication histories. The patients’ sociodemographic charac-
teristics (age, body mass index, race, comorbidities, and mar-
ital, menopausal, smoking, and alcohol status) and clinical
characteristics (estrogen/progesterone receptor status, HER-2
status, breast cancer staging, histology, and comorbidities)
were obtained from their electronic medical records. Data on
the patients’ medication use were collected from their elec-
tronic prescription records, covering the period from the date
of diagnosis (biopsy results) to 1 year post-chemotherapy. As
the data were collected from electronic records held by public
institutions, neither the patients’ clinical/prescription records
from private practices nor their non-prescribed medication
were included.
Medicine classification and definitions
The medication types were classified according to the WHO’s
Anatomical Therapeutic Chemical (ATC) classification sys-
tem [16]. Each medication was classified at the first
(anatomical) and second (therapeutic/pharmacological) levels
of the ATC classification system. The therapeutic drug cate-
gories were further classified as “medications for chronic dis-
eases” or “other medications” according to an adapted list of
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20 chronic diseases generated by the Office of the Secretary of
Health, US Department of Human and Health Services
(OASH) [17]. The OASH’s list was modified to include thy-
roid disorders.
“Before chemotherapy” was defined as the period between
the date of disease diagnosis (inclusive) and the first day of the
first cycle of chemotherapy (exclusive). “During chemothera-
py” was defined as the period from the first day of the first
cytotoxic chemotherapy cycle to the last day of the final cy-
totoxic chemotherapy cycle. “Post-chemotherapy” was de-
fined as the 1-year period beginning on the last day of the
final cytotoxic chemotherapy cycle (including a 1-year
trastuzumab maintenance period) (Fig. 1).
Statistical analysis
Descriptive statistics were used to summarize both categorical
data (frequencies and percentages) and continuous data
(means and standard deviations). Post hoc Bonferroni tests
and repeated measures analysis of variance (ANOVA) with
Greenhouse-Geisser correction were used to assess the signif-
icance of the differences between the numbers of chronic dis-
ease medication classes taken before, during. and after che-
motherapy. All of the data analysis was performed using the
Statistical Package for the Social Sciences program (version
16.0).
Results
Demographics (Table 1)
A total of 107 patients met the criteria for participation in
the study; all of whose data were included in the final analysis.
The mean (± SD) age of the population was 51.1 (±8.4), and
the majority of the patients [83 (77.6 %)] were 45 years old
and above. The mean (± SD) body mass index of the popula-
tion was 24.6 (±4.3) kg/m2, and 36 (33.6 %) and 23 (21.5 %)
patients were overweight and obese, respectively. Most of the
patients were Chinese [84 (78.5 %)], married [81 (75.6 %)],
non-smokers [92 (86.0 %)], and non-drinkers [99 (92.5 %)].
The majority of the patients had been diagnosed with stage
II breast cancer [49 (45.8 %)] and presented with invasive
ductal carcinoma (IDC) [92 (86.0 %)]. Significant proportions
of the sample had estrogen receptor-positive [82 (76.6 %)] and
progesterone receptor-positive [74 (69.2 %)] breast cancer.
Almost half of the patients [50 (46.7 %)] manifested comor-
bidities. Hypertension was the most common comorbidity [26
(24.3 %)], followed by hyperlipidemia [14 (13.1 %)] and di-
abetes mellitus [6 (5.6 %)]. Thirty patients (28.0 %) manifest-
ed one comorbidity, and 13 (12.2 %) manifested two
comorbidities.
Prevalence of therapeutic medication classes before,
during, and after chemotherapy (Table 2)
Prior to chemotherapy, the chronic disease medication
types most commonly used by the sampled patients were in
the cardiovascular anatomical class: calcium channel blockers
[13 (12.1 %)], lipid-lowering medications [12 (11.2 %)], and
agents acting on the renin-angiotensin-aldosterone-system
(RAAS) [7 (6.5 %)]. The main therapeutic classes used were
analgesics [83 (77.6 %)], medications for acid-related disor-
ders [44 (44.1 %)], and non-steroidal anti-inflammatory drugs
(NSAIDs) [46 (43.0 %)].
Cardiovascular medication types remained the most com-
mon anatomical class of chronic disease medication during
chemotherapy: lipid-lowering medications [12 (11.2 %)], cal-
cium channel blockers [11 (10.3 %)], and agents acting on the
RAAS [9 (8.4 %)]. The use of other medication during che-
motherapy was limited to the following three main anatomical
classes: (i) alimentary tract and metabolism: anti-emetics and
anti-nauseants [107 (100 %)], drugs for acid-related disorders
[45 (42.1 %)], drugs for constipation [44 (41.1 %)], and
stomatological preparations [29 (27.1 %)]; (ii) nervous sys-
tem: analgesics [83 (77.6 %)] and psycholeptics [24
(22.4 %)]; and (iii) dermatologicals: topical corticosteroids
[31 (29.0 %)], emollients, and protectives [25 (23.4 %)].
Hormonal therapy was the most prevalent therapeutic class
of chronic disease medication during the 1-year post-chemo-
therapy period [83 (77.6%)]. There was a noteworthy increase
in the use of chronic medication from the musculoskeletal
anatomical class, specifically bone disease medication [13
(12.1 %)] and non-steroidal anti-inflammatory drugs [28
(26.2 %)]. An increase was also observed in the use of
psychoanaleptics [4 (3.7 %)]. Other significant therapeutic
Diagnosis
First day of first 
cycle of cytotoxic 
chemotherapy
Last day of final 
cycle of cytotoxic 
chemotherapy
Before
chemotherapy
During 
chemotherapy
1 year post-chemotherapy
Fig. 1 Description of the stages
of patients’ treatment journey
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classes of medication used after chemotherapy were vitamins
[77 (72.0 %)], analgesics [48 (44.9 %)], emollients and pro-
tectives [38 (35.5 %)], topical corticosteroids [27 (25.2 %)],
and muscle relaxants [18 (16.8 %)].
Numbers of chronic disease medication classes before,
during, and after chemotherapy
Before chemotherapy, 33 (30.9 %) patients received medica-
tion for chronic diseases. During chemotherapy, the number of
patients [37 (34.6 %)] receiving medication for chronic dis-
eases increased. This number increased further during the
post-chemotherapy period [92 (86.0 %)] (Table 3). In addi-
tion, the mean number (± SD) of chronic disease medication
classes increased between the pre-chemotherapy and post-
chemotherapy periods: from 0.53 (±1.04) (before chemother-
apy) to 0.62 (±1.08) (during chemotherapy) and to 1.63
(±1.35) (post-chemotherapy). A statistically significant in-
crease was observed in the number of medication classes pre-
scribed for chronic diseases as treatment progressed through
Table 1 Demographics (N=107)
Characteristics N %
Age (±SD) (year) at diagnosis
Mean 51.1±8.4
<35 4 3.7
35–44 20 18.7
45–54 40 37.5
55–64 39 36.4
65 and above 4 3.7
Body mass index (± SD) (kg/m2) at diagnosis
Mean 24.6±4.6
Underweight (<18.5) 4 3.7
Normal (18.5–22.9) 44 41.2
Overweight (23.0–27.4) 36 33.6
Obese (≥27.5) 23 21.5
Race
Chinese 84 78.5
Malay 14 13.1
Indian 2 1.9
Othera 7 6.5
Marital status
Married 81 75.6
Single 19 17.8
Divorced 5 4.7
Widowed 2 1.9
Menopausal status
Pre-menopausal 46 43.0
Peri-menopausal 2 1.9
Post-menopausal 59 55.1
Smoking status
Smoker 7 6.5
Non-smoker 92 86.0
Missing data 8 7.5
Alcohol status
Yes 8 7.5
No 99 92.5
Estrogen receptor status
Positive 82 76.6
Negative 25 23.4
Progesterone receptor status
Positive 74 69.2
Negative 33 30.8
HER-2 status
Positive 50 46.7
Negative 57 53.3
Staging
I 27 25.2
II 49 45.8
III 31 29.0
Histology
Invasive ductal carcinoma (IDC) 92 86.0
Table 1 (continued)
Characteristics N %
Invasive lobular carcinoma (ILC) 5 4.7
IDC + ILC 3 2.8
Others 7 6.5
Comorbidities
No significant comorbidities 57 53.3
Hypertension 26 24.3
Hyperlipidemia 14 13.1
Diabetes mellitus 6 5.6
Thyroid disorders 5 4.7
Hepatobiliary disorders 5 4.7
Cardiac disorders 4 3.7
Migraine 3 2.8
Eczema 3 2.8
Asthma 2 1.9
Musculoskeletal disorders 2 1.9
Depression 2 1.9
Gastrointestinal disorders 2 1.9
Otherb 4 3.7
Number of comorbidities (±SD)
Mean 0.75±1.00
0 57 53.3
1 30 28.0
2 13 12.2
3 4 3.7
4 3 2.8
a Filipinos, Sikh, Myanmese
b Acute myeloid leukemia, thalassemia, neurofibromatosis type 1,
endometriosis
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Table 2 Medication use before, during, and after chemotherapy (N=107)
Anatomical class Therapeutic classb For
managing
chronic
diseasea
Number of patients (%)
Before
chemotherapy
During
chemotherapy
Post-
chemotherapy
Alimentary tract and metabolism Drugs used in diabetes ✓ 4 (3.7) 4 (3.7) 4 (3.7)
Stomatological preparations 1 (0.9) 29 (27.1) 5 (4.7)
Drugs for acid-related disorders 44 (41.1) 45 (42.1) 25 (23.4)
Drugs for functional gastrointestinal
disorders
0 6 (5.6) 1 (0.9)
Anti-emetics and anti-nauseants 20 (18.7) 107 (100.0) 16 (15.0)
Drugs for constipation 8 (7.5) 44 (41.1) 14 (13.1)
Antidiarrheal, intestinal anti-inflammatories/
anti-infectives
1 (0.9) 18 (16.8) 9 (8.4)
Vitaminsc 13 (12.1) 12 (11.2) 77 (72.0)
Vitamin B-containing 3 (2.8) 14 (13.1) 33 (30.8)
Vitamin C 9 (8.4) 1 (0.9) 3 (2.8)
Vitamin D/calcium-containing 3 (2.8) 11 (10.3) 66 (61.7)
Multivitamins 1 (0.9) 5 (4.7) 2 (1.9)
Mineral supplements 2 (1.9) 1 (0.9) 0
Blood and blood-forming organs Antithrombotic agents ✓ 2 (1.9) 2 (1.9) 2 (1.9)
Anti-anemic preparations 4 (3.7) 11 (10.3) 6 (5.6)
Cardiovascular Cardiac therapy ✓ 1 (0.9) 1 (0.9) 1 (0.9)
Diuretics ✓ 3 (2.8) 3 (2.8) 2 (1.9)
Beta-blocking agents ✓ 7 (6.5) 7 (6.5) 12 (11.2)
Calcium channel blockers ✓ 13 (12.1) 11 (10.3) 12 (11.2)
Agents acting on RAAS system ✓ 7 (6.5) 9 (8.4) 11 (10.3)
Lipid-modifying agents ✓ 12 (11.2) 12 (11.2) 14 (13.1)
Vasoprotectives 0 6 (5.6) 4 (3.7)
Dermatologicals Antifungals 2 (1.9) 9 (8.4) 10 (9.3)
Emollients and protectives 1 (0.9) 25 (23.4) 38 (35.5)
Antibiotics and chemotherapeutics 5 (4.7) 10 (9.3) 13 (12.1)
Corticosteroids 4 (3.7) 31 (29.0) 27 (25.2)
Antiseptics and disinfectants 3 (2.8) 6 (5.6) 5 (4.7)
Genitourinary system and sex
hormones
Gynecological anti-infectives and antiseptics 1 (0.9) 1 (0.9) 3 (2.8)
Other gynecological 2 (1.9) 1 (0.9) 0
Systemic hormonal preparations Thyroid therapy ✓ 2 (1.9) 2 (1.9) 3 (2.8)
Corticosteroids 0 10 (9.3) 2 (1.9)
Anti-infectives for systemic use Antivirals for hepatitis (ribavirin, entecavir) ✓ 2 (1.9) 2 (1.9) 3 (2.8)
Antibacterials 40 (37.4) 37 (34.6) 38 (35.5)
Antimycotics 0 1 (0.9) 2 (1.9)
Antivirals (aciclovir) 0 7 (6.5) 5 (4.7)
Antineoplastic and
immunomodulating agents
Endocrine therapy ✓ 0 5 (4.7) 83 (77.6)d
AIs 0 1 (0.9) 34 (31.8)
Tamoxifen 0 3 (2.8) 53 (49.5)
Goserelin 0 1 (0.9) 1 (0.9)
Granulocyte colony-stimulating factors 0 44 (41.1) 0
Musculoskeletal system Glucosamine products ✓ 2 (1.9) 1 (0.9) 1 (0.9)
Anti-gout preparations ✓ 0 0 1 (0.9)
Drugs used for treatment of bone diseases ✓ 1 (0.9) 3 (2.8) 13 (12.1)
Non-steroidal anti-inflammatory drugs 46 (43.0) 14 (13.1) 28 (26.2)
Muscle relaxants 1 (0.9) 8 (7.5) 18 (16.8)
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the three periods (p<0.0001). Post hoc analysis revealed a
significant difference between the numbers of chronic disease
medication classes used pre-chemotherapy and post-
chemotherapy (p<0.0001) and between the numbers used
during and after chemotherapy (p<0.0001).
Discussion
This study has successfully characterized the changes in med-
ication use by survivors of ESBC during their treatment jour-
neys until 1 year post-chemotherapy. In summary, cardiovas-
cular medication was the most common class of medication
prescribed for chronic diseases, with a significant increase in
the use of hormonal therapies, bone disease medication, and
psychoanaleptics during the post-chemotherapy period. The
number of medication classes prescribed for chronic disease
management also increased during the post-chemotherapy pe-
riod, in comparison with the periods before and during che-
motherapy. Dermatologicals and medication associated with
the alimentary tract, the metabolism, and the nervous system
were the most prevalent forms of non-chronic disease medi-
cation during chemotherapy. In contrast, vitamins, dermato-
logicals, musculoskeletal medication, and analgesics were
predominant during the post-chemotherapy period. The re-
sults of this study make an important contribution to the liter-
ature on the numerous treatment-related complications [7, 8,
18, 19] and chronic disease management needs associated
with breast cancer.
The characterization of medication use offers invaluable
insights into the medication management needs of a popula-
tion of breast cancer survivors, potentially facilitating the de-
velopment of dedicated medicine management services for
women who have achieved complete remission after treat-
ment. Between ESBC diagnosis and the beginning of chemo-
therapy, changes to the participants’ medication were made
primarily to manage treatment-related complications. The
trend in medication use during chemotherapy suggests that
the patients experienced treatment-related complications in
the following forms: gastrointestinal side effects (mucositis,
nausea, vomiting, constipation, dyspepsia), which are com-
monly exhibited by patients receiving taxanes and
anthracycline-containing regimens; neurological effects (anx-
iety, insomnia); and dermatological side effects (probably sec-
ondary to taxanes).
In contrast, most of the changes in medication post-
chemotherapy reflected the introduction of adjuvant hormonal
therapies and medication to manage the long-term psychoso-
cial effects of cancer and its treatment. Long-term hormonal
therapy in the form of AIs or tamoxifen causes side effects that
must be managed. This explains the prevalence of medication
for osteoporosis (bisphosphonates, calcium/vitamin D supple-
ments) and musculoskeletal symptoms (NSAIDs, analgesics,
muscle relaxants, glucosamine), to manage AI-associated
musculoskeletal effects, and the increased use of
Table 2 (continued)
Anatomical class Therapeutic classb For
managing
chronic
diseasea
Number of patients (%)
Before
chemotherapy
During
chemotherapy
Post-
chemotherapy
Nervous system Psychoanaleptics ✓ 0 1 (0.9) 4 (3.7)
Analgesics 83 (77.6) 43 (40.2) 48 (44.9)
Anti-epileptics 0 1 (0.9) 4 (3.7)
Psycholeptics 6 (8.6) 24 (22.4) 11 (10.3)
Other nervous system drugs 2 (1.9) 0 3 (2.8)
Respiratory system Drugs for obstructive airway diseases ✓ 2 (1.9) 2 (1.9) 2 (1.9)
Sore throat preparations 10 (9.3) 36 (33.6) 32 (29.9)
Cough and cold preparations 10 (9.3) 31 (29.0) 46 (43.0)
Antihistamines for systemic use 4 (3.7) 47 (43.9) 43 (40.2)
Sensory organs Ophthalmological anti-infectives 0 7 (6.5) 7 (6.5)
Ophthalmological lubricants 1 (0.9) 10 (9.3) 10 (9.3)
Ophthalmological anti-inflammatories 1 (0.9) 0 2 (1.9)
a OASH list of 20 chronic diseases (with modifications) [17]
bWHO ATC classification system [16]
c The number of patients does not add up to 107 (N) because some patients were using different vitamins concurrently
d The number of patients does not add up to 107 (N) because some patients switched endocrine therapy types or received multiple therapies
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psychoanaleptics (antidepressants) to manage menopausal
symptoms associated with tamoxifen (hot flushes, anxiety,
sleep disturbance). It is important to note that the effects of
estrogen deprivation were not solely due to hormonal therapy
but were probably compounded by the significant reduction in
estrogen levels in peri- and post-menopausal women, who
made up more than half of the sample population [40
(57.1 %)]. In addition, glucosamine, analgesics, and
NSAIDs may have been used to manage osteoarthritis, as
the majority of the population exhibited osteoarthritis risk fac-
tors [20–22] associated with gender (female), weight (over-
weight/obese), and age (elderly). The use of psychoanaleptics
probably reflects the need to manage the long-term psychoso-
cial effects of cancer and its treatment [18, 19].
The significant increase in the burden of medication for
chronic diseases from the periods before and during chemo-
therapy to the post-chemotherapy period was primarily due to
the introduction of hormonal therapies in addition to pre-
existing cardiovascular medication. Therefore, the breast can-
cer survivors in our population are likely to face medication
management problems such as reduced adherence and adverse
effects. In a recent systematic review, breast cancer survivors
were found to show suboptimal adherence and persistence
rates in response to adjuvant hormonal therapy (31–73 % dis-
continuation rates) [23], which may compromise the long-
term survival benefits of such therapy. Adherence was posi-
tively associated with the number of medication types taken at
baseline, referral to an oncologist and earlier diagnosis, and
negatively associated with treatment side effects and follow-
up with a general practitioner (as compared with an oncolo-
gist) [23]. This demonstrates the importance of ongoing
follow-up in the oncology setting and the need to manage
adverse effects to facilitate adherence to adjuvant hormonal
therapy. These imperatives are especially important for our
breast cancer survivor population, as only a minority had re-
ceived long-term medication for chronic diseases before
start ing hormonal therapy. It is also essential to
simultaneously monitor and manage the use of medication
for other pre-existing chronic diseases such as hypertension
and hyperlipidemia. Middle-aged non-cancer patients have
been reported to show suboptimal adherence to antihyperten-
sives [24] and cardiovascular medication such as lipid-
lowering medications for primary or secondary prevention,
potentially compromising their cardiovascular-associated
mortality and morbidity benefits. Such information contains
major implications to our breast cancer survivors. In this
study, our patients tend to be young (average of 50 years)
and diagnosed with few comorbidities; such demographics
are very s imi lar to the nat ional average among
Singaporeans. For example, the prevalence of hypertension
is 24 % in our study which is similar to the national survey
(23.5 %) [25]. Hence, medication compliance remains an im-
portant issue, and clinicians must ensure that these survivors
adhere to their prescribed adjuvant hormonal therapies and
chronic medications.
Primary care is likely to become vital to ESBC survivors’
long-term follow-up treatment and management, due to the
growth of this population and their diverse medication man-
agement needs, such as the long-term monitoring of hormonal
therapy, chronic disease management, and the management of
long-term treatment/disease-related complications after che-
motherapy. Although oncology specialists continue to play
critical roles in diagnosis and initial treatment, the activities
of primary care providers (general practitioners and commu-
nity pharmacists) have been expanded to cover early cancer
screening, post-treatment follow-up and surveillance for can-
cer recurrence, screening and management of the long-term
effects of cancer, and its treatment, medication management,
health promotion, and chronic disease management [9, 26].
As a result, numerousmodels of cancer survivorship care have
been developed and discussed in the literature [27–29], with
the aim of establishing a coordinated care partnership between
oncology specialists and primary care providers. Primary care
providers are likely to become responsible for managing the
Table 3 Number of medication
classes for chronic diseases taken
by each patient before, during,
and after chemotherapy (N=107)
Number of medication classes
for chronic diseases
Number of patients (%)
Before chemotherapy During chemotherapy Post-chemotherapy
0 74 (69.1) 70 (65.4) 15 (14.0)
1 22 (20.6) 21 (19.6) 49 (45.7)
2 3 (2.8) 8 (7.5) 22 (20.6)
3 5 (4.7) 5 (4.7) 11 (10.3)
4 1 (0.9) 1 (0.9) 5 (4.7)
≥5 2 (1.9) 2 (1.9) 5 (4.7)
Mean number of medication
classes for chronic diseases±SD*
0.53±1.04 0.62±1.08 1.63±1.35
*p<0.0001, obtained by repeated measures ANOVAwith Greenhouse-Geisser correction
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medication of breast cancer survivors during the post-
chemotherapy phase. Furthermore, rising health costs demand
that the long-term management of breast cancer survivors is
delegated to the primary setting and that medication manage-
ment is effective.
Although primary care may have an increasingly large part
to play in the management of cancer survivors, the roles of
healthcare workers in the tertiary setting remain crucial, as the
majority of breast cancer survivors follow-up with their on-
cologists in their first year after chemotherapy. Oncology
pharmacists are in the best position to understand these pa-
tients’ diverse medication management needs (both cancer-
related and non-cancer-related), and they need to be part of
the multidisciplinary team to manage the long-term complica-
tions experienced by this group of patients. A more concrete
understanding of the needs of breast cancer survivors will aid
the development of individualized cancer survivorship plans
in our setting to improve the coordination of care and make
effective use of our pharmacists’ diverse skill sets in the mul-
tidisciplinary management of breast cancer survivors.
This study has several limitations. The extent of the pa-
tients’ adherence to the prescribed medications was unknown.
However, compared with interviews or questionnaires, this
method of data collection minimized the risk of self-
reporting errors and interviewer bias. We were also able to
track changes in medication throughout the patients’ treatment
journeys, enabling us to identify trends in medication use at
different stages of treatment. The study was also limited by the
small size of the sample and the lack of a control population
with which to compare medication use. However, this sample
size was reasonable, as it captured the demographic character-
istics of the majority of patients diagnosed with ESBC. Lastly,
as the study was retrospective, causal relationships could not
be definitively established.
Conclusions
Given the increasing global population of ESBC survivors
and the extensive literature on the prevalence of chronic dis-
eases and disease-/treatment-related complications experi-
enced by these patients, ESBC survivors’medication manage-
ment can no longer be overlooked. Our findings suggest that
ESBC survivors are likely to receive numerous forms of long-
term medication, of which the most common are hormonal
therapy and pre-existing cardiovascular medication. In addi-
tion, we show that the medication use of breast cancer survi-
vors undergoes several changes from the pre- to post-
chemotherapy periods. These changes are usually made to
manage treatment-related complications. These findings pro-
vide preliminary insights into the treatment-related complica-
tions experienced by breast cancer survivors in our local pop-
ulation and their chronic disease management needs. These
insights will help both oncology specialists and primary care
providers to assess patients’ needs during long-term follow-up
treatment, as well as guiding the development of dedicated
medication management services for ESBC survivors.
Future researchers should compare the medication use of
ESBC survivors with that of a healthy population to obtain
clearer information on the trends in medication use and, more
importantly, the medication management needs of breast can-
cer survivors.
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